BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference
February 17 2020 - 1:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading
developer of autologous cellular therapies for highly debilitating
neurodegenerative diseases, announced that Ralph
Kern, MD, MHSc, Chief Operating Officer and Chief Medical
Officer, will provide a clinical update on the Company’s ALS and MS
trials and present insights on the future growth strategy of
BrainStorm at the Noble Capital Markets’ Sixteenth Annual Investor
Conference, taking place February 16-18, 2020 at the Hard Rock
Hotel & Casino, Hollywood, Florida.
BrainStorm has a fully enrolled 200-patient
Phase 3 clinical trial evaluating repeat intrathecal administration
of NurOwn® cellular therapeutic (autologous MSC-NTF cells) in
amyotrophic lateral sclerosis (ALS). In late October 2019, the
Data and Safety Monitoring Board (DSMB) completed the second
planned interim safety analysis for the first 106 patients who
received repeat dosing of NurOwn in the Phase 3 ALS trial.
Additionally, BrainStorm is enrolling patients
in an investigational Phase 2 clinical trial of NurOwn for
progressive MS, a disease with enormous unmet medical need.
Presentation Details:
Title: |
|
BrainStorm Corporate Update for Current and Future
Investors |
Presenter: |
|
Ralph Kern M.D., CMO, BrainStorm Cell Therapeutics |
Date: |
|
Monday, February 17, 2020 |
Time: |
|
12:00 PM Eastern Time |
Click Here For the Webcast of
Brainstorm’s Presentation
** The video webcast will be available starting
February 18, 2020 for 90 days **
About BrainStorm Cell Therapeutics
Inc. BrainStorm Cell
Therapeutics Inc. is a leading developer of innovative
autologous adult stem cell therapeutics for debilitating
neurodegenerative diseases. The Company holds the rights to
clinical development and commercialization of the
NurOwn® Cellular Therapeutic Technology Platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement as well as through its own patents, patent
applications and proprietary know-how. Autologous MSC-NTF cells
have received Orphan Drug status designation from the U.S.
Food and Drug Administration (U.S. FDA) and
the European Medicines Agency (EMA) in ALS. Brainstorm
has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056),
investigating repeat-administration of autologous MSC-NTF cells at
six sites in the U.S., supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a BLA filing
for U.S. FDA approval of autologous MSC-NTF cells in ALS.
Brainstorm received U.S. FDA clearance to initiate a
Phase 2 open-label multi-center trial of repeat intrathecal dosing
of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718)
in December 2018 and has been enrolling clinical trial
participants since March 2019. For more information, visit the
company's website.
About Noble Capital Markets,
Inc.Noble Capital Markets (“Noble”) is a research driven
boutique investment bank that has supported small & microcap
companies since 1984. As a FINRA and SEC licensed broker dealer
Noble provides institutional-quality equity research, merchant and
investment banking, wealth management and order execution services.
In 2005, Noble established NobleCon, an investor conference that
has grown substantially over the last decade. In 2018 Noble
launched www.channelchek.com - a new investment community dedicated
exclusively to small and micro-cap companies and their industries.
Channelchek is tailored to meet the needs of self-directed
investors and financial professionals. Channelchek is the first
service to offer institutional-quality research to the public, for
FREE at every level without a subscription. More than 6,000
emerging growth companies are listed on the site, with growing
content including webcasts, podcasts, and balanced news.
Safe-Harbor Statement
Statements in this announcement other than
historical data and information, including statements regarding
future clinical trial enrollment and data, constitute
"forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics
Inc.'s actual results to differ materially from those stated
or implied by such forward-looking statements. Terms and phrases
such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",
and similar terms and phrases are intended to identify these
forward-looking statements. The potential risks and uncertainties
include, without limitation, BrainStorm’s need to raise additional
capital, BrainStorm’s ability to continue as a going concern,
regulatory approval of BrainStorm’s NurOwn® treatment
candidate, the success of BrainStorm’s product development programs
and research, regulatory and personnel issues, development of a
global market for our services, the ability to secure and maintain
research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm’s
NurOwn® treatment candidate to achieve broad acceptance as a
treatment option for ALS or other neurodegenerative diseases,
BrainStorm’s ability to manufacture and commercialize the
NurOwn® treatment candidate, obtaining patents that provide
meaningful protection, competition and market developments,
BrainStorm’s ability to protect our intellectual property from
infringement by third parties, heath reform legislation, demand for
our services, currency exchange rates and product liability claims
and litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTSCorporate: Uri
Yablonka Chief Business Officer BrainStorm Cell
Therapeutics Inc. Phone: 646-666-3188
uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR PR Phone:
+1.646.677.1839 sean.leous@icrinc.com
Or
Katie Gallagher | Account Director, PR and
MarketingLaVoieHealthScience Strategic CommunicationsO:
617-374-8800 x109M:
617-792-3937kgallagher@lavoiehealthscience.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Sep 2023 to Sep 2024